Safety and Effectiveness Study of a Fiber Supplement for Weight Loss

Obesity Clinical Trial

Official title:

Safety and Efficacy of Glucomannan for Weight Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00613600
• Other study ID #: RTF-GM
• Status: Completed
• Phase: Phase 2
• First received: January 31, 2008
• Last updated: December 1, 2011
• Start date: February 2008
• Est. completion date: July 2009

Study information

• Verified date: December 2011
• Source: Rush University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Overweight and obesity are serious and growing problems within the United States. The usual approaches to weight loss-dieting, exercise, and behavioral interventions-rarely result in long-term weight loss. Therefore, we will evaluate the safety and efficacy of glucomannan, a fiber supplement that has promising weight loss effects.

Description:

The primary objective of this exploratory project is to evaluate the safety and efficacy of a highly viscous, water-soluble fiber supplement, glucomannan, for achieving weight loss in overweight and moderately obese individuals. Overweight and obesity are major public health problems in the U.S. that account for substantial morbidity, mortality, and healthcare costs. Conventional approaches to weight loss are largely ineffective, particularly for long-term weight loss and maintenance. Thus, there is a critical need for safe and effective adjunctive treatments. A few, limited studies suggest that glucomannan supplementation is associated with weight loss, is well-tolerated, and has a favorable safety profile.

In this preliminary study, the target population will be overweight and moderately obese individuals, a population that accounts for nearly 50% of all U.S. adults. The specific aims of the project are to: 1) describe the safety of glucomannan for achieving weight loss in overweight and moderately obese individuals, and 2) describe the efficacy of glucomannan for achieving weight loss in overweight and moderately obese individuals. Participants will take glucomannan supplements daily for eight weeks in a double-blind, placebo-controlled, randomized clinical trial. Safety and efficacy outcome measures include: gastrointestinal symptoms/tolerance, hepatic panel, serum creatinine, weight, body composition, diet intake, hunger/fullness, lipid profile, blood glucose, and C-reactive protein. Examination of the safety and efficacy of glucomannan for achieving weight loss will extend our understanding of additional treatments that may be effective in combating a significant public health problem.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• age > or = 18 and < or = 65 years

• body mass index (BMI) > or = 25 and < or = 35 at study entry

• speak and understand English (since translated versions of study tools have not been validated)

• for females only: without childbearing potential or negative HCG hormone blood test and use of an appropriate form of contraception

• signed informed consent form and HIPAA research authorization

Exclusion Criteria:

• current use of fiber supplements or intolerance to fiber supplements

• untreated/unstable metabolic conditions known to influence weight status (e.g., hypothyroidism, type 2 diabetes mellitus)

• gastrointestinal disorders that might cause complications or influence motility or satiety (e.g., diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal narrowing or obstruction, difficulty swallowing)

• Stage II hypertension (> or = 160/100 mg Hg) or dyslipidemia (fasting LDL cholesterol > or = 160 mg/dL; total cholesterol > or = 240 mg/dL; triglycerides > 200 mg/dL; HDL < or = 40 mg/dL)

• fasting serum glucose > 126 mg/dL

• acute or unstable cardiovascular, pulmonary, hepatic, renal, or psychiatric disorders

• conditions for which weight loss may not be appropriate (e.g., HIV/AIDS, cancer)

• use of medications that might affect weight or food absorption (e.g., diuretics, glucocorticoids, anorexigenic agents, Orlistat, laxatives)

• use of CAM therapies that might affect weight (e.g., acupuncture, Hoodia)

• weight change of > 5% body weight within 3 months of entry into the study

• active eating disorders or active participation in a weight loss program

• renal function impairment as evidenced by a history of renal disease or a serum creatinine > 2.0 mg/dL

• liver function impairment as evidenced by a history of liver disease or liver enzyme elevations > three times the upper limit of normal (i.e., ALT > 150 u/L and/or AST > 165 u/L)

• evidence of depression as determined by a weighted score of > or = 16 on the Center for Epidemiological Studies Depression Scale (CES-D), as this may affect eating behavior and adherence to the study protocol

• currently consumes > or = 10 alcoholic drinks/week, as determined by self-report

• currently smokes cigarettes due to the effects of nicotine on appetite and C-reactive protein levels

• use of illicit drugs currently or in the last six months, as determined by self-report

• for females only: pregnant, less than 6 months postpartum or 6 months post-termination of pregnancy, or currently lactating, due to lack of safety data in this population

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Obesity
• Overweight
• Weight Loss

Intervention

Dietary Supplement:
• Glucomannan
Two 665 mg capsules of glucomannan three times a day for 8 weeks
• Inert microcrystalline cellulose
Two capsules of inert microcrystalline cellulose three times a day for eight weeks

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Rush University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight loss		8 weeks	No
Secondary	Body composition		8 weeks	No
Secondary	Dietary intake		8 weeks	No
Secondary	Hunger and fullness		8 weeks	No
Secondary	Lipid profile		8 weeks	No
Secondary	Fasting blood glucose		8 weeks	No
Secondary	C-reactive protein		8 weeks	No
Secondary	Gastrointestinal symptoms and tolerance		8 weeks	Yes
Secondary	Hepatic panel		8 weeks	Yes
Secondary	Serum creatinine		8 weeks	Yes